|Chemical and physical data|
|Molar mass||142.8 kg/mol|
|(what is this?)|
Ensituximab (NPC-1C) is a chimeric monoclonal antibody under development for as a candidate for treatment of cancers. The target of the antibody is uncertain and is described as "human colorectal and pancreatic carcinoma-associated antigens", a set of tumor antigens isolated from human cancers. The target might be Mucin 5AC.
The antibody was discovered by scientists at Neogenix Oncology using tumor antigens that had been identified years earlier by Ariel Hollinshead; the founder of Neogenix had founded a prior company based on Hollinshead's work as well. Neogenix worked with Selexis to develop the CHO cell line expressing ensituximab and also worked with Goodwin Biotechnology Inc on process development.
Ensituximab was granted orphan drug designation for pancreatic cancer by the FDA in 2010. Results from a small Phase II trial in people with pancreatic or colon cancer presented in 2012 were not promising with regard to efficacy in treating pancreatic cancer.
In 2011 Neogenix was forced to declare bankruptcy because the SEC opened an investigation into its use of unregistered broker-dealers in the course of raising $30M, and it could not raise further funds; in 2012 Neogenix sold its assets to a group of its investors who had formed a company called Precision Biologics.
- "Statement On A Nonproprietary Name Adopted By The USAN Council: Ensituximab" (PDF). American Medical Association.
- "Ensituximab". NCI Drug Dictionary. Retrieved 31 January 2017.
- Strimpakos, Alexios S.; Syrigos, Kostas N.; Saif, Muhammad Wasif (10 March 2012). "Novel Agents in Early Phase Clinical Studies on Refractory Pancreatic Cancer". JOP. Journal of the Pancreas. 13 (2): 166–168. ISSN 1590-8577. PMID 22406592.
- Morrison, Trista (July 11, 2007). "Neogenix Uses Cancer Vaccine And Antibody Approaches". BioWorld Today.
- Neogenix Oncology, Inc. - Pharmaceuticals & healthcare - Deals and alliances profile. (2015). London: Global Data Ltd.
- "Press ReleaseL Selexis and Neogenix Oncology Execute Commercial License Agreement - Selexis SA". Selexis SA. 5 January 2011.
- "From Vaccines To Monoclonal Antibodies: Creating Milestones In Cancer Theranostics". Frost & Sullivan. 14 September 2007.
- Staff (1 December 2010). "FDA Pipeline Preview, December 2010 (Ezogabine, Solesta, Dutasteride, Finasteride, Octaplex, SF1126, MP4CO, Ensituximab, Naloxone, CBLB502)". Formulary Journal.
- Davie, Alexander J. (5 October 2012). "Neogenix Oncology: A Good Case Study on Securities Law (Non)Compliance by a High Growth Company – Part 1: How It All Happened". Strictly Business.. "Neogenix Oncology: A Good Case Study on Securities Law (Non)Compliance by a High Growth Company – Part 2: What Neogenix Did". Strictly Business. 24 October 2012.. "Neogenix Oncology: A Good Case Study on Securities Law (Non)Compliance by a High Growth Company – Part 3: When the Genie Can’t Be Put Back in the Bottle". Strictly Business. 17 November 2012.
- "Ensituximab". AdisInsight. Retrieved 30 January 2017.
|This monoclonal antibody-related article is a stub. You can help Wikipedia by expanding it.|
|This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.|